Grant: Operating Grant - Priority Announcement: Aging (Bridge Funding)
Ottawa Hospital Research Institute
$100,000.00
D-serine and plasticity
FY 2008-09
Summary
Learning and memory require information exchange between brain cells in circuits that pair at least two different
environmental inputs in space and time. For example, when we meet someone new, visual and auditory pathways are
activated and this information is routed to the hippocampus, a brain region in which the convergent activity leads to storage
of information. Memory is the ability of the brain to re-call established circuits so that the next time we see the person or hear
his/her voice we remember his/her name. For reasons that remain elusive, these circuits are particularly vulnerable to
dysfunction in Alzheimer's disease (AD) patients. Subtle changes in these circuits are responsible for the death of brain cells
in regions of the brain where information is stored, one of which is the hippocampus. The death of populations of brain cells
in AD patients apparently occurs over a prolonged time period of many years, this is why, slowly but surely, AD patients lose
their memory and even their personalities. Due to advances in genetic engineered mice, we have generated a mouse line
with a phenotype that are similar to some of the characteristics of AD patients. Indeed, we have initiated some experiments
with these mice and we found that they behave like animals with memory deficits. I propose to study the hippocampus of
these animals using a multidisciplinary approach in order to better understand the chemicals known to be related to memory
impairment of AD patients. It is also hoped that the findings of our investigation will help to develop innovative treatments
for AD patients.
Department
Program
Operating Grant - Priority Announcement: Aging (Bridge Funding)
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
176076
Name
Bergeron Richard
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Biological and Clinical Aspects of Aging
Projecttitle
D-serine and plasticity
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Aging (Bridge Funding)
Keyworddelim
Dementia; Glutamate; Hippocampus; Nmda Receptor; Whole-Cell Patch-Clamp
Abstract
Learning and memory require information exchange between brain cells in circuits that pair at least two different
environmental inputs in space and time. For example, when we meet someone new, visual and auditory pathways are
activated and this information is routed to the hippocampus, a brain region in which the convergent activity leads to storage
of information. Memory is the ability of the brain to re-call established circuits so that the next time we see the person or hear
his/her voice we remember his/her name. For reasons that remain elusive, these circuits are particularly vulnerable to
dysfunction in Alzheimer's disease (AD) patients. Subtle changes in these circuits are responsible for the death of brain cells
in regions of the brain where information is stored, one of which is the hippocampus. The death of populations of brain cells
in AD patients apparently occurs over a prolonged time period of many years, this is why, slowly but surely, AD patients lose
their memory and even their personalities. Due to advances in genetic engineered mice, we have generated a mouse line
with a phenotype that are similar to some of the characteristics of AD patients. Indeed, we have initiated some experiments
with these mice and we found that they behave like animals with memory deficits. I propose to study the hippocampus of
these animals using a multidisciplinary approach in order to better understand the chemicals known to be related to memory
impairment of AD patients. It is also hoped that the findings of our investigation will help to develop innovative treatments
for AD patients.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bergeron, Richard
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~